Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis
James A. Hutchinson, Katharina Kronenberg, Paloma Riquelme and 21 more
Nature Communications · 2021
doi:10.1038/s41467-021-21572-y (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Checkpoint blocking therapies are used to treat metastatic melanoma, but can have adverse immune-mediated effects, including liver pathology. Here the authors identify an expanded pool of CD4+ effector memory T cells resulting from prior CMV exposure as a risk factor for this adverse effect in these patients.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.